ArticleFrontiers in nutrition2026
Secretor status-dependent modulation of
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Human milk oligosaccharides (HMOs) are structurally diverse carbohydrates found in high concentrations in human milk, supporting infant immune development and gut microbiota colonization. Their composition is influenced by maternal Secretor (Se) status, determined by the FUT2 gene. While immunological HMO effects are increasingly recognized, the influence of an infant's own Se status on immune responses remains understudied. This study explores how peripheral blood mononuclear cells (PBMCs) from Se-positive (Se+) and Se-negative (Se-) individuals respond to Se+ and Se- HMOs under bacterial and viral stimulation. Methods: PBMCs from 14 healthy adult donors, classified based on FUT2 expression, were exposed to 0.1% pooled Se+ or Se- HMOs, individual HMOs (2'-fucosyllactose and 3-fucosyllactose), and immune triggers (αCD3/CD28, LPS, and/or Poly I:C) for 24-48 h. Cytokine secretion (IFNγ, IL10, IL13, TNFα) was measured. Results: Basal cytokine secretion did not differ between Se+ and Se- PBMCs. Upon stimulation, Se+ PBMCs secreted more IL10, particularly in response to Se+ or Se- HMOs. Individual HMOs did not replicate effects seen with pooled mixtures, highlighting the importance of HMO complexity. Under LPS stimulation, TNFα secretion was significantly reduced only with genotype-matched HMOs, suggesting Secretor-specific immune modulation. Conclusion: This is the first study showing that PBMC cytokine responses are shaped mainly by host Secretor status than HMO composition. Both genotype and HMO profile influence immune reactivity and should be considered in HMO research and personalized infant nutrition strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.